FDA approves Lilly’s Inluriyo to treat advanced breast cancer
The approval was based on results from the Phase III EMBER-3 trial in 256 patients.
Cancer
FDA to priority-review Daiichi Sankyo and AZ’s Enhertu sBLA
Akeso gains NMPA approval for cadonilimab to treat cervical cancer
ASCO25: J&J’s trispecific antibody shows 100% response in Phase I multiple myeloma study
Epsilogen acquires TigaTx to expand pan-isotope cancer antibody pipeline
NICE green lights two blood cancer therapies for NHS use
World Cancer Day: WHO warns of rising cancer burden in Southeast Asia
People-focused cancer care demands policy support
